Navigation Links
CorNova Announces Addition of Andrew T. Jay, D.M.D., M.B.A., to its Board of Directors
Date:3/3/2009

BURLINGTON, Mass., Mar. 3 /PRNewswire/ -- CorNova, Inc. today announced the addition of Andrew T. Jay, D.M.D., to its board of directors. The addition increases board membership to 4.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070206/CLTU213LOGO )

Dr. Jay, 46, is the managing partner of the Medical Solutions Fund of Siemens Venture Capital GmbH, the venture organization for Siemens AG. Prior to joining Siemens Venture Capital, he was an Institutional Investor-ranked medical technology analyst with both Alex. Brown and Wachovia Securities, where his coverage included cardiovascular device companies. Dr. Jay received his D.M.D. from the University of Pennsylvania and his M.B.A. from the Kellogg School at Northwestern. He earned his B.S. from Rensselaer Polytechnic Institute.

"Adding such an accomplished and experienced venture investor and medical technology analyst to our board is an important step in the development of CorNova," said S. Eric Ryan, M.D., CorNova's chief executive officer. "His advice will be invaluable as our company advances our FiberHalo(TM) angioplasty catheter toward commercialization, and we move forward to CE-Mark approval for our Valecor Platinum(TM) Coronary Stent System."

"CorNova's FiberHalo catheter and Valecor Platinum Coronary Stent System address two separate billion dollar market opportunities with approaches that could sell well on their own or shift market share significantly in the hands of a major player in the cardiovascular space," said Dr. Jay. He is taking this role independent of his activity at Siemens Venture Capital.

About CorNova

CorNova is a developer of next-generation endovascular products designed to integrate new technologies into existing products and procedures, resulting in better patient outcomes without added procedure time, cost and patient risk. The company's FiberHalo(TM) stent deployment and post-dilatation angioplasty balloon catheters are designed to provide stent lumen area measurement within the angioplasty catheter itself. CorNova is also developing a pre-dilatation form of the FiberHalo catheter that can obtain information on an arterial plaque's composition, allowing for superior treatment selection, and the Valecor Platinum(TM) Coronary Stent, an advanced "bare-metal stent" with an ion-infused pure platinum surface that has shown superior performance and anti-restenosis properties compared to current bare-metal stents. For more information, visit www.cornova.com.


'/>"/>
SOURCE CorNova, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Marketing Technology Solutions Announces Strong 2008 Growth and Web Site Enhancements for QualityHealth.com
2. Genoptix Announces Participation at Barclays Capital Global Healthcare Conference
3. Marinus Pharmaceuticals, Inc. Announces Positive Results of its Phase 2 Clinical Trial of Ganaxolone as Adjunctive Therapy in Adults With Partial Onset Seizures
4. Osteotech Announces Fourth Quarter and Full Year 2008 Earnings Release and Conference Call; Company to Release Financial Results on Wednesday, March 4, 2009 and Host Call on Thursday, March 5, 2009
5. WellPoint Announces Appearances at Upcoming Conferences
6. Align Technology Announces International Availability of Invisalign Teen(TM)
7. MHA Announces: Launch of New Website
8. National Instruments Announces New Suite of Prototyping Hardware to Lower Development Time and Costs
9. Lilly Announces Leadership Changes
10. Availity Announces Support of Project SwipeIT
11. The Vitality Group Announces Expansion to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... December 08, 2016 , ... The ... the Undersea and Hyperbaric Medical Society (UHMS), the leading authority in hyperbaric medicine. ... safety. Only a few hospitals and facilities have earned this distinction. This is ...
(Date:12/8/2016)... JENNERSVILLE, Pa. (PRWEB) , ... December 08, 2016 ... ... Penn Medicine Southern Chester County, a Property owned by an affiliate of Seavest, ... 72,000 square foot Penn Medicine Southern Chester County ambulatory care center (ACC) was ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... David ... with global law firm Greenberg Traurig, LLP, will speak at DeviceTalks West, Dec. 12, ... of the DeviceTalks series, and attorneys from the firm’s global Life Sciences & Medical ...
(Date:12/8/2016)... ... December 08, 2016 , ... Catalent Pharma Solutions, ... biologics and consumer health products, today announced that it had joined the Pharmaceutical ... a non-profit organization to unite pharmaceutical and healthcare companies that share a vision ...
(Date:12/8/2016)... ... December 08, 2016 , ... Today’s patients are encouraged ... in mind, SIGVARIS has created a new line of anti-embolism stockings to help ... provide the benefits of graduated compression when transitioning from recovery to early rehabilitation. ...
Breaking Medicine News(10 mins):
(Date:12/9/2016)... Dec 9, 2016 Research and Markets has announced ... Business Report" report to their offering. ... The report also analyses the market by the following ... comprehensive analytics for the US, Canada , ... , Latin America , and Rest of World. ...
(Date:12/9/2016)... Dec. 9, 2016 aTyr Pharma, Inc. (Nasdaq: ... of Physiocrine-based therapeutics to address severe, rare diseases, today announced that ... BMO Prescriptions for Success Healthcare Conference at the InterContinental Barclay Hotel ... 14, 2016, at 4:20 p.m. ET. About aTyr ... aTyr ...
(Date:12/9/2016)... DIEGO , Dec. 9, 2016  Forge ... Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: ... targeting ,LpxC, for the treatment of bacterial infections ... has been recognized as an attractive antibacterial target ... a lack of suitable chemical starting points has ...
Breaking Medicine Technology: